DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Efficacy and Tolerability of DITROPAN XL (Oxybutynin Chloride) Versus DETROL LA (Tolterodine Tartrate) in Treatment of Overactive Bladder

Information source: Alza Corporation, DE, USA
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Urinary Incontinence

Intervention: oxybutynin chloride (Drug)

Phase: Phase 3

Status: Completed

Sponsored by: Alza Corporation, DE, USA

Official(s) and/or principal investigator(s):
Alza Corporation Clinical Trial, Study Director, Affiliation: ALZA


The purpose of this study is to compare the efficacy of DITROPAN® XL (oxybutynin chloride) Extended-Release Tablets and DETROL® LA (tolterodine tartrate extended-release capsules) in the reduction of urge urinary incontinence episodes during a 12-week treatment period in patients with overactive bladder. The secondary objective is to compare the tolerability of DITROPAN® XL (oxybutynin chloride) and DETROL® LA (tolterodine tartrate) during a 12-week treatment period.

Clinical Details

Official title: Comparison of the Efficacy and Tolerability of DITROPAN XL and DETROL LA in the Treatment of Overactive Bladder

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Primary outcome: The number of weekly urge urinary incontinence (Urge-UI) episodes at week 12, adjusted for the baseline value

Secondary outcome: The number of total urinary incontinence (Total-UI) episodes at week 12; Void frequency at week 12; Urge-UI ,Total-UI, and Void frequence at weeks 2, 4, and 8; tolerability of the treatments during the 12-week treatment phase.

Detailed description: The objective of this study is to compare the efficacy and tolerability of DITROPAN® XL 10 mg once-daily and DETROL�® LA 4 mg once-daily in the reduction of urge urinary incontinence episodes in female patients with overactive bladder. This is a multicenter, randomized, double-blind, parallel-group study with two active treatments. Screened patients are qualified for the study based on information obtained from seven consecutive 24-hour urinary diaries completed during the Baseline Week, and other eligibility criteria. Qualifying patients receive 12 weeks of treatment with DITROPAN® XL or DETROL® LA, with clinical visits at the end of Weeks 2, 4, 8, and 12. Safety evaluations during the study include the collection of adverse events, laboratory tests including blood chemistry and urinalysis, physical examinations, vital signs (blood pressure and heart rate) and post-void residual urine volume. Over-encapsulated DITROPAN® XL, 10 mg tablets once-daily by mouth or over-encapsulated DETROL® LA, 4 mg capsules once daily by mouth. The treatment phase of the study runs for 12 weeks.


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Female.


Inclusion Criteria:

- Participants who are able to differentiate urinary incontinence episodes associated

with urgency from urinary incontinence episodes not associated with urgency

- during the 7 day baseline period have 21 to 60 urge urinary incontinence (Urge-UI)

episodes, a greater number of Urge-UI episodes than urinary incontinence not associated with urge, and an average of 10 or more voids per 24 hours

- are in good general health as determined by medical history, physical examination

(general, genital, pelvic, and rectal), laboratory tests and urinalysis

- if taking antihypertension medication, must be on a stable dose

- and if of child-bearing potential, practicing an acceptable method of birth control,

and must have a negative pregnancy test at Visit 2 and Visit 3 Exclusion Criteria:

- Participants with known, treatable genitourinary conditions (identified on history or

on examination) that may cause incontinence (e. g., urinary tract infection, interstitial cystitis, urinary tract obstruction, urethral diverticulum, bladder tumor, bladder stone)

- have given birth or have had pelvic, vaginal or bladder surgery less than 6 months

before study enrollment

- with a second post-void residual urine volume > 150 mL at the time of screening

(determined by abdominal ultrasound)

- with significant medical problems or other organ abnormality that places them at risk

from participating in the study or at a significant risk of developing complete urinary retention

- with significant impairment of the liver or kidneys as determined by laboratory

assessments or hematuria (red blood cells in microscopic urinalysis)

Locations and Contacts

Additional Information

Last updated: December 7, 2010

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017